Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Catalent Announces Agreement with CiRA, Kyoto University

Published: Friday, March 14, 2014
Last Updated: Friday, March 14, 2014
Bookmark and Share
Agreement for one of the first regenerative therapies to employ iPS cells in humans.

Catalent Pharma Solutions has announced an agreement with the Center for iPS Cell Research and Application (CiRA) at Kyoto University in Japan to make a major advancement toward one of the first regenerative human therapies with induced pluripotent stem (iPS) cells applicable to humans.

Under this agreement, Catalent manufactures an anti-CORIN monoclonal antibody using its proprietary GPEx® cell line expression technology for a planned clinical research project to develop an iPS cell-based transplant therapy for Parkinson’s disease at CiRA, which is directed by Professor Doctor Shinya Yamanaka, the joint winner of the Nobel Prize in Physiology or Medicine in 2012 for “the discovery that mature cells can be reprogrammed to become pluripotent”.

The anti-CORIN monoclonal antibody was discovered and developed through collaborative research between CiRA and KAN Research Institute, Inc., a research subsidiary of a major Japanese pharmaceutical company, Eisai Co., Ltd- http://www.kan-research.co.jp/english/index.html).

Catalent has already engineered cell lines producing the anti-CORIN monoclonal antibody for CiRA using their GPEx technology, and the antibody has been shown to be useful for sorting CORIN-expressing cells in in vitro studies at CiRA.

Under the agreement, Catalent will conduct further clonal selection and manufacturing of the monoclonal antibody under a properly conditioned environment for CiRA, which will use the antibody to select dopaminergic neurons derived from iPS cells and plans to transplant the selected cells into patients in a possible clinical research program upon receipt of regulatory approval. Catalent will also support CiRA, with formulation, production, and sterile fill/finish of the monoclonal antibody, aspects of the project that could not be handled within academia.

“It is a great honor to work with a team led by world renowned Professor Doctor Jun Takahashi,” commented Shingo Nakamura, Catalent’s Director of Biologics, Japan. “We are very excited to help accelerate the development of a unique regenerative therapy using our GPEx technology and look forward to working with CiRA to bring better treatments to market faster.”

Jonathan Arnold, Vice President and General Manager of Catalent Biologics, added, “We are witnessing an increased demand for biologics in the Asia Pacific market. Our GPEx technology, our expertise, and access to Antibody Drug Conjugates, combined with our investment in state-of-the art manufacturing facilities, mean that we are ideally placed to act as a partner to CiRA in this exciting project.”

Catalent’s GPEx technology produces high-yielding, stable mammalian cell lines and has been successfully applied in the manufacture of more than 500 different recombinant proteins, over 30 of which are now undergoing clinical trials or being supplied commercially.

Antibiotic selection and traditional gene amplification are not required when using GPEx technology, resulting in shorter clonal cell line development timelines.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More Than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Catalent To Acquire Pharmatek
The acquisition adds expanded drug development services and spray drying technology.
Wednesday, September 14, 2016
Catalent, Zumutor Collaborate
Collaboration aims to develop antibodies with enhanced ADCC activity.
Friday, August 05, 2016
Catalent, Palatin Technologies Announce Agreement
Partnership aims to support the product launch of Palatin’s bremelanotide pen injector product, which is used to treat FSD.
Thursday, July 07, 2016
Catalent Launches FastChain Service
Company has announced the launch of its FastChain service to meet increasing need for speed & flexibility in global clinical trials.
Thursday, June 30, 2016
Catalent Invests $4.6M To Further Expand Asia–Pacific Clinical Trials
Company provide of advanced delivery technologies and development solutions for drugs, biologics, consumer health products and global clinical supply services.
Friday, February 05, 2016
Catalent Announces Appointment of Sally Langa
Appointment of Ms. Langa as new Vice President of Development and Analytical Services.
Friday, January 29, 2016
Catalent to Open New Clinical Supply Facility in Japan
Construction is expected to be validated and operational in the second quarter of 2016.
Thursday, January 21, 2016
Catalent Announces Research Collaboration with Roche
Collaboration focuses on development of novel molecules using SMARTag technology to couple different therapeutic modalities.
Thursday, January 14, 2016
Catalent, Roche Collaborate On SMARTag™
Collaboration focuses on development of novel molecules using SMARTag technology to couple different therapeutic modalities.
Thursday, January 14, 2016
Catalent Biologics Announces the Appointment of Kevin Hambly
Company appoints Mr. Hambly to the position of Vice President, Business Development and Licensing.
Tuesday, December 15, 2015
Catalent Biologics Expands Capabilities
Company announces multi-site expansion of its analytical and process development capabilities.
Thursday, November 26, 2015
Catalent Biologics Adds New Technology Platform
Company has signed an exclusive licensing agreement with Excelimmune to access ACT platform.
Thursday, July 09, 2015
Catalent Awarded Grant as Part of Vaccine Research Consortium
Goal of the consortium is to develop a scalable manufacturing process for vaccines that are stable and temperature independent.
Friday, April 24, 2015
Catalent & Sanofi to Collaborate
Collaboration on SMARTag™ antibody-drug conjugate technology with Sanofi’s proprietary antibodies.
Thursday, January 22, 2015
Catalent and SELLAS Sign Exclusive Agreement
Agreement for therapeutic reprofiling of zolpidem.
Friday, December 12, 2014
Scientific News
Point of Care Diagnostics - A Cautious Revolution
Advances in molecular biology, coupled with the miniaturization and improved sensitivity of assays and devices in general, have enabled a new wave of point-of-care (POC) or “bedside” diagnostics.
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
One Step Closer to Precision Medicine for Chronic Lung Disease Sufferers
A study led by University of North Carolina at Chapel Hill, and National Jewish Health, has provided evidence of links between SNPs and known COPD blood protein biomarkers.
Blood Pressure Drug May Boost Effectiveness of Lung Cancer Treatment
Researchers at Imperial College London have suggested that the blood pressure drug may make a type of lung cancer treatment more effective.
Insight into Eye Diseases
Scientists recreate zebrafish cell regeneration from retinal stem cells in mice.
New Discovery May Benefit Farmers Worldwide
Scientists have shown how a crop-microbe 'team' protect against fungal infection.
Antibodies Paving the Way to HIV Vaccine
Researchers uncover factors responsible for the formation of broadly neutralizing HIV antibodies in humans.
Designing Drugs with a Whole New Toolbox
Researchers develop methods to design small, targeted proteins with shapes not found in nature.
Protein Studies Discover Molecular Secrets
Two protein studies have mapped proteins that reveal the secrets to recycling carbon and healing cells.
Tapping Evolution to Improve Biotech Products
Researchers show how 'ancestral sequence reconstruction' can be used to guide engineering of a blood clotting protein.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!